Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.
Vietnam Investment Review on MSN8h
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian CancerInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...
The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.
BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth ...
Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback